357 related articles for article (PubMed ID: 37298342)
21. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
22. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis.
Su R; Bennett M; Jacobs S; Hunter T; Bailey C; Krishnan E; Rosen G; Chung L
J Rheumatol; 2011 Apr; 38(4):693-701. PubMed ID: 21285162
[TBL] [Abstract][Full Text] [Related]
23. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
24. [Interstitial lung disease in connective tissue disorders].
Carmier D; Diot É; Guilleminault L; Marchand-Adam S
Rev Prat; 2014 Sep; 64(7):941-5. PubMed ID: 25362775
[TBL] [Abstract][Full Text] [Related]
25. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
26. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.
Koo SM; Uh ST
Korean J Intern Med; 2017 Jul; 32(4):600-610. PubMed ID: 28704913
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
Mendoza FA; Allawh T; Jimenez SA
Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
[TBL] [Abstract][Full Text] [Related]
28. Clinical Presentation of Connective Tissue Disease Patients with and without Interstitial Lung Disease: A Retrospective Study.
Sambataro G; Libra A; Spicuzza L; Palmucci S; Conti P; Spagnolo E; Colaci M; Malatino L; Orlandi M; Sambataro D; Vancheri C
Respiration; 2023; 102(6):405-415. PubMed ID: 37231870
[TBL] [Abstract][Full Text] [Related]
29. Management of interstitial lung disease associated with connective tissue disease.
Mathai SC; Danoff SK
BMJ; 2016 Feb; 352():h6819. PubMed ID: 26912511
[TBL] [Abstract][Full Text] [Related]
30. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
31. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
32. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study.
Kilinc AA; Arslan A; Yildiz M; Kucur M; Adrovic A; Barut K; Sahin S; Cokugras H; Kasapcopur O
Rheumatol Int; 2020 Oct; 40(10):1701-1706. PubMed ID: 31784789
[TBL] [Abstract][Full Text] [Related]
33. Air pollutants and development of interstitial lung disease in patients with connective tissue disease: a population-based case-control study in Taiwan.
Chen HH; Yong YM; Lin CH; Chen YH; Chen DY; Ying JC; Chao WC
BMJ Open; 2020 Dec; 10(12):e041405. PubMed ID: 33372076
[TBL] [Abstract][Full Text] [Related]
34. [Interstitial lung disease related to systemic connective tissue diseases].
Fiedorczyk M; Rojewska J; Kowal-Bielecka O; Sierakowski S
Przegl Lek; 2005; 62(12):1471-4. PubMed ID: 16786776
[TBL] [Abstract][Full Text] [Related]
35. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
36. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
37. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
38. Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study.
de Oliveira Martins LV; Oliveira SM; Silvatti J; de Amorim FG; Agapito Tito CV; Kayser C
J Clin Rheumatol; 2022 Mar; 28(2):e532-e538. PubMed ID: 34609336
[TBL] [Abstract][Full Text] [Related]
39. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
40. Biological treatments and connective tissue disease associated interstitial lung disease.
Panopoulos ST; Sfikakis PP
Curr Opin Pulm Med; 2011 Sep; 17(5):362-7. PubMed ID: 21597375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
